Right Eye / Cheek

Summary

This is the dataset used in the AAMD 2024 Plan Study and publicly available via the ProKnow Quality Systems website.

This patient has a recurrent squamous cell carcinoma of the right face anterior to the maxilla having received MOHS twice with cranial nerve V2 involvement to Meckel’s Cave.

Gallery

1. Two variations of variable-thickness boluses, here shown with user-defined goal buildup depths of 15 mm and 10 mm (min buildup to underlying PTV)
2. Four-panel view in the p.d software showing an OptiBol with 15 mm goal buildup
3. OptiBol variations without (left) and with (right) optional alignment guides
4. Depth-volume histograms for the voxels in the underlying PTV shown with no bolus vs. OptiBol 15 mm

Details on Depth-Volume Histograms (Gallery Item 4)

Variable-Thickness OptiBol (Goal 15 mm to Target)

• 100% of the target voxels have min depth ≥ 10 mm (0% target < 10 mm)
• 97% of the target voxels have min depth ≥ 14.25 mm (where 14.25 mm is 95% of the goal buildup for this bolus design)
• 94% of the target voxels have min depth ≥ 15 mm

No Bolus

• Only 57% target voxels have min depth ≥ 10 mm (43% target < 10 mm)
• Only 41% of the target voxels have min depth ≥ 14.25 mm
• Only 39% of the target voxels have min depth ≥ 15 mm